المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı., Özkocaman, Vildan, Demirkaya, Metin, AAH-1854-2021, 6603145040, 24331130000

مصطلحات موضوعية: Oncology, Hodgkin lymphoma, Resistant/relapsed disease, Programmed death 1 (PD-1) blocker, Nivolumab, Brentuxımab vedotın, PD-1 blockade, Adolescent, Adult, Aged, Antibodies, Monoclonal, Antineoplastic, Agents, Disease-free survival, Female, Hodgkin disease, Humans, Immunoconjugates, Male, Middle aged, Retrospective studies, Stem cell transplantation, Young adult, Brentuximab Vedotin, Hodgkin's Disease, Refractory Materials, Mycophenolate mofetil, Programmed death 1 receptor, Steroid

الوصف: "Çalışmada 32 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır” ; Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile. Patients and methods: We present a retrospective analysis of 82 patients (median age: 30 years; range: 18-75) with relapsed/refractory HL treated with nivolumab in a named patient program from 24 centers throughout Turkey. The median follow-up was 7 months, and the patients had a median of 5 (2-11) previous lines of therapy. Fifty-seven (70%) and 63 (77%) had been treated by stem-cell transplantation and brentuximab vedotin, respectively. Results: Among 75 patients evaluated after 12 weeks of nivolumab treatment, the objective response rate was 64%, with 16 complete responses (CR; 22%); after 16 weeks, it was 60%, with 16 (26%) patients achieving CR. Twenty patients underwent subsequent transplantation. Among 11 patients receiving allogeneic stem-cell transplantation, 5 had CR at the time of transplantation and are currently alive with ongoing response. At the time of analysis, 41 patients remained on nivolumab treatment. Among the patients who discontinued nivolumab, the main reason was disease progression (n = 19). The safety profile was acceptable, with only four patients requiring cessation of nivolumab due to serious adverse events (autoimmune encephalitis, pulmonary adverse event, and two cases of graft-versus-host disease aggravation). The 6-month overall and progression-free survival rates were 91.2% (95% confidence interval: 0.83-0.96) and 77.3% (0.66-0.85), respectively. Ten patients died during the follow-up; one of these was judged to be treatment-related. Conclusions: Nivolumab represents a novel option for patients with cHL ...

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; Annals of Oncology; Yurt içi; Sanayi; Beköz, H. vd. (2017). ''Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience''. Annals of Oncology, 28(10), 2496-2502.; https://doi.org/10.1093/annonc/mdx341Test; https://www.sciencedirect.com/science/article/pii/S0923753419349452Test; http://hdl.handle.net/11452/32082Test; 000411827200025; 2-s2.0-85030557671; 2496; 2502; 28; 10

الإتاحة: https://doi.org/10.1093/annonc/mdx341Test
http://hdl.handle.net/11452/32082Test
https://www.sciencedirect.com/science/article/pii/S0923753419349452Test

المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı., Özkocaman, Vildan, Demirkaya, Metin, AAH-1854-2021, 6603145040, 24331130000

مصطلحات موضوعية: Oncology, Hodgkin lymphoma, Resistant/relapsed disease, Programmed death 1 (PD-1) blocker, Nivolumab, Brentuxımab vedotın, PD-1 blockade, Adolescent, Adult, Aged, Antibodies, Monoclonal, Antineoplastic, Agents, Disease-free survival, Female, Hodgkin disease, Humans, Immunoconjugates, Male, Middle aged, Retrospective studies, Stem cell transplantation, Young adult, Brentuximab Vedotin, Hodgkin's Disease, Refractory Materials, Mycophenolate mofetil, Programmed death 1 receptor, Steroid

الوصف: "Çalışmada 32 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır” ; Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile. Patients and methods: We present a retrospective analysis of 82 patients (median age: 30 years; range: 18-75) with relapsed/refractory HL treated with nivolumab in a named patient program from 24 centers throughout Turkey. The median follow-up was 7 months, and the patients had a median of 5 (2-11) previous lines of therapy. Fifty-seven (70%) and 63 (77%) had been treated by stem-cell transplantation and brentuximab vedotin, respectively. Results: Among 75 patients evaluated after 12 weeks of nivolumab treatment, the objective response rate was 64%, with 16 complete responses (CR; 22%); after 16 weeks, it was 60%, with 16 (26%) patients achieving CR. Twenty patients underwent subsequent transplantation. Among 11 patients receiving allogeneic stem-cell transplantation, 5 had CR at the time of transplantation and are currently alive with ongoing response. At the time of analysis, 41 patients remained on nivolumab treatment. Among the patients who discontinued nivolumab, the main reason was disease progression (n = 19). The safety profile was acceptable, with only four patients requiring cessation of nivolumab due to serious adverse events (autoimmune encephalitis, pulmonary adverse event, and two cases of graft-versus-host disease aggravation). The 6-month overall and progression-free survival rates were 91.2% (95% confidence interval: 0.83-0.96) and 77.3% (0.66-0.85), respectively. Ten patients died during the follow-up; one of these was judged to be treatment-related. Conclusions: Nivolumab represents a novel option for patients with cHL ...

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; Annals of Oncology; Yurt içi; Sanayi; Beköz, H. vd. (2017). ''Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience''. Annals of Oncology, 28(10), 2496-2502.; https://doi.org/10.1093/annonc/mdx341Test; https://www.sciencedirect.com/science/article/pii/S0923753419349452Test; http://hdl.handle.net/11452/32082Test; 000411827200025; 2-s2.0-85030557671; 2496; 2502; 28; 10

الإتاحة: https://doi.org/10.1093/annonc/mdx341Test
http://hdl.handle.net/11452/32082Test
https://www.sciencedirect.com/science/article/pii/S0923753419349452Test

المؤلفون: Altay, Canan, Seçil, Mustafa, Demir, Tevfik, Atik, Tahir, Akıncı, Gülçin, Kutbay, Nilüfer Özdemir, Temeloğlu, Ela Keskin, Şimşir, Ilgin Yıldırım, Özışık, Seçil, Demir, Leyla, Tuna, Emine Burçin, Aytaç, Hasibe, Onay, Hüseyin, Akıncı, Barış

المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Endokrinoloji Anabilim Dalı., orcid:0000-0002-1684-1053, Eren, Erdal, AAM-1734-2020, AAH-1155-2021, 36113153400

مصطلحات موضوعية: Radiology, nuclear medicine & medical imaging, Congenital generalized lipodystrophy, Familial partial lipodystrophy, Severe insulin-resistance, Body-fat distribution, Gene-expression, Regional differences, Ptrf mutationsi, Identification, Heterogeneity, Deficiency, Adipose tissue, Adolescent, Adult, Child, Diagnosis, differential, Female, Humans, Lipodystrophy, Magnetic resonance imaging, Male, Middle aged, Whole body Imaging, Young adult, Metreleptin, Acquired Partial Lipodystrophy, Caveolin 1, Creatinine

الوصف: PURPOSE We aimed to investigate residual adipose tissue with whole-body magnetic resonance imaging to differentiate between subtypes of lipodystrophy. METHODS A total of 32 patients 12 with congenital generalized lipodystrophy [CGL], 1 with acquired generalized lipodystrophy [AGL], 12 with familial partial lipodystrophy [FPLD], and 7 with acquired partial lipodystrophy [APL]) were included. RESULTS Despite generalized loss of metabolically active adipose tissue, patients with CGL1 caused by AGPAT2 mutations had a significant amount of residual adipose tissue in the scalp, earlobes, retro-orbital region, and palms and soles. No residual adipose tissue was noted particularly in the head and neck, palms and soles in CGL2 caused by BSCL2 mutations. CGL4 caused by mutations in the PTRF gene was characterized with well-preserved retro-orbital and bone marrow fat in the absence of any visible residual adipose tissue in other areas. No residual adipose tissue was observed in AGL. Despite loss of subcutaneous fat, periarticular adipose tissue was preserved in the lower limbs of patients with FPLD. Retro-orbital adipose tissue was surprisingly preserved in APL, although they lacked head and neck fat. CONCLUSION Lipodystrophies are a heterogeneous group of disorders characterized by generalized or partial loss of adipose tissue, which can be congenital or acquired. Our results suggest that residual adipose tissue characteristics can help distinguish different subtypes of lipodystrophy.

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; Diagnostic and Interventional Radiology; Yurt içi; Sanayi; Altay, C. vd. (2017). ''Determining residual adipose tissue characteristics with MRI in patients with various subtypes of lipodystrophy''. Diagnostic and Interventional Radiology, 23(6), 428-434.; https://doi.org/10.5152/dir.2017.17019Test; https://www.dirjournal.org/en/determining-residual-adipose-tissue-characteristics-with-mri-in-patients-with-various-subtypes-of-lipodystrophy-131769Test; http://hdl.handle.net/11452/30424Test; 000414273500004; 2-s2.0-85032956287; 428; 434; 23

الإتاحة: https://doi.org/10.5152/dir.2017.17019Test
http://hdl.handle.net/11452/30424Test
https://www.dirjournal.org/en/determining-residual-adipose-tissue-characteristics-with-mri-in-patients-with-various-subtypes-of-lipodystrophy-131769Test

المؤلفون: Altay, Canan, Seçil, Mustafa, Demir, Tevfik, Atik, Tahir, Akıncı, Gülçin, Kutbay, Nilüfer Özdemir, Temeloğlu, Ela Keskin, Şimşir, Ilgin Yıldırım, Özışık, Seçil, Demir, Leyla, Tuna, Emine Burçin, Aytaç, Hasibe, Onay, Hüseyin, Akıncı, Barış

المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Endokrinoloji Anabilim Dalı., orcid:0000-0002-1684-1053, Eren, Erdal, AAM-1734-2020, AAH-1155-2021, 36113153400

مصطلحات موضوعية: Radiology, nuclear medicine & medical imaging, Congenital generalized lipodystrophy, Familial partial lipodystrophy, Severe insulin-resistance, Body-fat distribution, Gene-expression, Regional differences, Ptrf mutationsi, Identification, Heterogeneity, Deficiency, Adipose tissue, Adolescent, Adult, Child, Diagnosis, differential, Female, Humans, Lipodystrophy, Magnetic resonance imaging, Male, Middle aged, Whole body Imaging, Young adult, Metreleptin, Acquired Partial Lipodystrophy, Caveolin 1, Creatinine

الوصف: PURPOSE We aimed to investigate residual adipose tissue with whole-body magnetic resonance imaging to differentiate between subtypes of lipodystrophy. METHODS A total of 32 patients 12 with congenital generalized lipodystrophy [CGL], 1 with acquired generalized lipodystrophy [AGL], 12 with familial partial lipodystrophy [FPLD], and 7 with acquired partial lipodystrophy [APL]) were included. RESULTS Despite generalized loss of metabolically active adipose tissue, patients with CGL1 caused by AGPAT2 mutations had a significant amount of residual adipose tissue in the scalp, earlobes, retro-orbital region, and palms and soles. No residual adipose tissue was noted particularly in the head and neck, palms and soles in CGL2 caused by BSCL2 mutations. CGL4 caused by mutations in the PTRF gene was characterized with well-preserved retro-orbital and bone marrow fat in the absence of any visible residual adipose tissue in other areas. No residual adipose tissue was observed in AGL. Despite loss of subcutaneous fat, periarticular adipose tissue was preserved in the lower limbs of patients with FPLD. Retro-orbital adipose tissue was surprisingly preserved in APL, although they lacked head and neck fat. CONCLUSION Lipodystrophies are a heterogeneous group of disorders characterized by generalized or partial loss of adipose tissue, which can be congenital or acquired. Our results suggest that residual adipose tissue characteristics can help distinguish different subtypes of lipodystrophy.

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; Diagnostic and Interventional Radiology; Yurt içi; Sanayi; Altay, C. vd. (2017). ''Determining residual adipose tissue characteristics with MRI in patients with various subtypes of lipodystrophy''. Diagnostic and Interventional Radiology, 23(6), 428-434.; https://doi.org/10.5152/dir.2017.17019Test; https://www.dirjournal.org/en/determining-residual-adipose-tissue-characteristics-with-mri-in-patients-with-various-subtypes-of-lipodystrophy-131769Test; http://hdl.handle.net/11452/30424Test; 000414273500004; 2-s2.0-85032956287; 428; 434; 23

الإتاحة: https://doi.org/10.5152/dir.2017.17019Test
http://hdl.handle.net/11452/30424Test
https://www.dirjournal.org/en/determining-residual-adipose-tissue-characteristics-with-mri-in-patients-with-various-subtypes-of-lipodystrophy-131769Test

المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı., Mıstık, Reşit, 6602564624

مصطلحات موضوعية: Infectious diseases, Baseline resistance, Hepatitis C virus, Mutation, Protease inhibitors, Genotype 1, Pegylated interferon, Antiviral agents, Virus genotypes, Ribavirin, Telaprevir, Simeprevir, Infection, Polymorphisms, Retreatment, Adult, Aged, 80 and over, Drug resistance, viral, Female, Genotype, Hepacivirus, Hepatitis C, chronic, Humans, Male, Middle aged, Oligopeptides, Proline

الوصف: Çalışmada 21 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır. ; Background: Drug resistance development is an expected problem during treatment with protease inhibitors (PIs), this is largely due to the fact that Pls are low-genetic barrier drugs. Resistance-associated variants (RAVs) however may also occur naturally, and prior to treatment with Pls, the clinical impact of this basal resistance remains unknown. In Turkey, there is yet to be an investigation into the hepatitis C (HCV) drug associated resistance to oral antivirals. Materials and methods: 178 antiviral-naive patients infected with HCV genotype 1 were selected from 27 clinical centers of various geographical regions in Turkey and included in the current study. The basal NS3 Pls resistance mutations of these patients were analyzed. Results: In 33 (18.5%) of the patients included in the study, at least one mutation pattern that can cause drug resistance was identified. The most frequently detected mutation pattern was T54S while R109K was the second most frequently detected. Following a more general examination of the patients studied, telaprevir (TVR) resistance in 27 patients (15.2%), boceprevir (BOC) resistance in 26 (14.6%) patients, simeprevir (SMV) resistance in 11 (6.2%) patients and faldaprevir resistance in 13 (7.3%) patients were detected. Our investigation also revealed that rebound developed in the presence of a Q80K mutation and amongst two V55A mutations following treatment with TVR, while no response to treatment was detected in a patient with a R55K mutation. Conclusion: We are of the opinion that drug resistance analyses can be beneficial and necessary in revealing which variants are responsible for pre-treatment natural resistance and which mutations are responsible for the viral breakthrough that may develop during the treatment. ; Kocaeli Üniversitesi Bilimsel Araştırma Projeleri Bölümü ; Türk Klinik Mikrobiyoloji ve Enfeksiyon Hastalıkları Derneği

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; International Journal of Infectious Diseases; Yurt içi; Yurt dışı; Sanayi; Altunok, E. S. vd. (2016). "Protease inhibitors drug resistance mutations in Turkish patients with chronic hepatitis C". ed. Petersen, E. ve Denmark, A. International Journal of Infectious Diseases, 50, 1-5.; https://doi.org/10.1016/j.ijid.2016.07.003Test; https://www.sciencedirect.com/science/article/pii/S1201971216311109Test; http://hdl.handle.net/11452/29837Test; 000388326300001; 2-s2.0-84979254596; 50

الإتاحة: https://doi.org/10.1016/j.ijid.2016.07.003Test
http://hdl.handle.net/11452/29837Test
https://www.sciencedirect.com/science/article/pii/S1201971216311109Test

المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı., Mıstık, Reşit, 6602564624

مصطلحات موضوعية: Infectious diseases, Baseline resistance, Hepatitis C virus, Mutation, Protease inhibitors, Genotype 1, Pegylated interferon, Antiviral agents, Virus genotypes, Ribavirin, Telaprevir, Simeprevir, Infection, Polymorphisms, Retreatment, Adult, Aged, 80 and over, Drug resistance, viral, Female, Genotype, Hepacivirus, Hepatitis C, chronic, Humans, Male, Middle aged, Oligopeptides, Proline

الوصف: Çalışmada 21 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır. ; Background: Drug resistance development is an expected problem during treatment with protease inhibitors (PIs), this is largely due to the fact that Pls are low-genetic barrier drugs. Resistance-associated variants (RAVs) however may also occur naturally, and prior to treatment with Pls, the clinical impact of this basal resistance remains unknown. In Turkey, there is yet to be an investigation into the hepatitis C (HCV) drug associated resistance to oral antivirals. Materials and methods: 178 antiviral-naive patients infected with HCV genotype 1 were selected from 27 clinical centers of various geographical regions in Turkey and included in the current study. The basal NS3 Pls resistance mutations of these patients were analyzed. Results: In 33 (18.5%) of the patients included in the study, at least one mutation pattern that can cause drug resistance was identified. The most frequently detected mutation pattern was T54S while R109K was the second most frequently detected. Following a more general examination of the patients studied, telaprevir (TVR) resistance in 27 patients (15.2%), boceprevir (BOC) resistance in 26 (14.6%) patients, simeprevir (SMV) resistance in 11 (6.2%) patients and faldaprevir resistance in 13 (7.3%) patients were detected. Our investigation also revealed that rebound developed in the presence of a Q80K mutation and amongst two V55A mutations following treatment with TVR, while no response to treatment was detected in a patient with a R55K mutation. Conclusion: We are of the opinion that drug resistance analyses can be beneficial and necessary in revealing which variants are responsible for pre-treatment natural resistance and which mutations are responsible for the viral breakthrough that may develop during the treatment. ; Kocaeli Üniversitesi Bilimsel Araştırma Projeleri Bölümü ; Türk Klinik Mikrobiyoloji ve Enfeksiyon Hastalıkları Derneği

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; International Journal of Infectious Diseases; Yurt içi; Yurt dışı; Sanayi; Altunok, E. S. vd. (2016). "Protease inhibitors drug resistance mutations in Turkish patients with chronic hepatitis C". ed. Petersen, E. ve Denmark, A. International Journal of Infectious Diseases, 50, 1-5.; https://doi.org/10.1016/j.ijid.2016.07.003Test; https://www.sciencedirect.com/science/article/pii/S1201971216311109Test; http://hdl.handle.net/11452/29837Test; 000388326300001; 2-s2.0-84979254596; 50

الإتاحة: https://doi.org/10.1016/j.ijid.2016.07.003Test
http://hdl.handle.net/11452/29837Test
https://www.sciencedirect.com/science/article/pii/S1201971216311109Test

المؤلفون: Şişman, Pınar

المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü., Uludağ Üniversitesi/Tıp Fakültesi/Temel Tıp Bilimleri Bölümü., Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı., Gül, Özen Öz, Dirican, Melahat, Bal, Ahmet Selim, Cander, Soner, Ertürk, Erdinç, AAI-1005-2021, ESK-6562-2022, IBB-8079-2023, CJH-1319-2022, AAJ-6536-2021, 26040787100, 6601919847, 57215130724, 25027068600, 7005488796

مصطلحات موضوعية: Medical laboratory technology, Neutrophil gelatinase-associated lipocalin (NGAL), Type 1 diabetes, Diabetic nephropathy, Kidney injury molecule-1, Tubular markers, Biomarkers, Disease, Pathophysiology, Proteinuria, Progression, Diagnosis, Damage, Adult, Case-control studies, Diabetes mellitus, type 1, Diabetic nephropathies, Female, Humans, Lipocalin-2, Male, ROC curve, Young adult, Middle aged, Neutrophil gelatinase associated lipocalin, Albümin, Creatinine, Biological marker, Lcn2 protein

الوصف: Background: Glomerular and tubulointerstitial damage plays a role in renal function failure in diabetic patients. While both serum and urine levels of neutrophil gelatinase-associated lipocalin (NGAL) show significantly increased levels in acute renal pathologies, the NGAL increase in active phase indicates a reversible condition in chronic cases. Materials and methods: 52 type 1 diabetic patients and 30 healthy volunteers participated in the study. The diabetic participants were separated into two groups as follows: a normoalbuminuria group consisting of those with an albumin/creatinine ratio less than 30 mg/g and an albuminuria group consisting of those with an albumin/creatinine ratio equal or greater than 30 mg/g. Albumin, creatinine and NGAL were measured in all participants. Results: Urinary NGAL median level was 21.1 ng/mL for diabetic patients and 11.9 ng/mL for healthy controls, and the difference between the two groups was statistically significant. When diabetic patients were compared as those with and without albuminuria, the median urinary NGAL levels of normoalbuminuria and albuminuria were 24.7 and 16.1 ng/mL, respectively, but the difference was not statistically significant. Statistically similar results were obtained through evaluation of the ratio of urinary NGAL excretion to creatinine excretion. The NGAL/Cr ratio was significantly higher in diabetic patients than in healthy controls, but no statistically significant difference was found between the diabetic patients with and without albuminuria. Conclusions: Urinary NGAL excretion in type 1 diabetic patients is found to be increased over a wide range, but it does not correlate with urinary albumin excretion. In this regard, urinary NGAL excretion should not be used as an alternative to microalbuminuria in detecting diabetic nephropathy. The greater amount of NGAL excretion among diabetic patients may be due to diabetic nephropathy with possible tubulointerstitial damage pathologies.

العلاقة: Makale - Uluslararası Hakemli Dergi; Clinical Laboratory; Sanayi; Şişman, P. vd. (2020). "Urinary neutrophil gelatinase-associated lipocalin (NGAL) as a marker of diabetic nephropathy in type 1 diabetic patients". Clinical Laboratory, 66(1,2), 9-16.; https://doi.org/10.7754/Clin.Lab.2019.190326Test; https://www.clin-lab-publications.com/article/3270Test; http://hdl.handle.net/11452/34388Test; 000545455000002; 2-s2.0-85078933657; 16; 66; 1-2

الإتاحة: https://doi.org/10.7754/Clin.Lab.2019.190326Test
http://hdl.handle.net/11452/34388Test
https://www.clin-lab-publications.com/article/3270Test

المؤلفون: Şişman, Pınar

المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü., Uludağ Üniversitesi/Tıp Fakültesi/Temel Tıp Bilimleri Bölümü., Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı., Gül, Özen Öz, Dirican, Melahat, Bal, Ahmet Selim, Cander, Soner, Ertürk, Erdinç, AAI-1005-2021, ESK-6562-2022, IBB-8079-2023, CJH-1319-2022, AAJ-6536-2021, 26040787100, 6601919847, 57215130724, 25027068600, 7005488796

مصطلحات موضوعية: Medical laboratory technology, Neutrophil gelatinase-associated lipocalin (NGAL), Type 1 diabetes, Diabetic nephropathy, Kidney injury molecule-1, Tubular markers, Biomarkers, Disease, Pathophysiology, Proteinuria, Progression, Diagnosis, Damage, Adult, Case-control studies, Diabetes mellitus, type 1, Diabetic nephropathies, Female, Humans, Lipocalin-2, Male, ROC curve, Young adult, Middle aged, Neutrophil gelatinase associated lipocalin, Albümin, Creatinine, Biological marker, Lcn2 protein

الوصف: Background: Glomerular and tubulointerstitial damage plays a role in renal function failure in diabetic patients. While both serum and urine levels of neutrophil gelatinase-associated lipocalin (NGAL) show significantly increased levels in acute renal pathologies, the NGAL increase in active phase indicates a reversible condition in chronic cases. Materials and methods: 52 type 1 diabetic patients and 30 healthy volunteers participated in the study. The diabetic participants were separated into two groups as follows: a normoalbuminuria group consisting of those with an albumin/creatinine ratio less than 30 mg/g and an albuminuria group consisting of those with an albumin/creatinine ratio equal or greater than 30 mg/g. Albumin, creatinine and NGAL were measured in all participants. Results: Urinary NGAL median level was 21.1 ng/mL for diabetic patients and 11.9 ng/mL for healthy controls, and the difference between the two groups was statistically significant. When diabetic patients were compared as those with and without albuminuria, the median urinary NGAL levels of normoalbuminuria and albuminuria were 24.7 and 16.1 ng/mL, respectively, but the difference was not statistically significant. Statistically similar results were obtained through evaluation of the ratio of urinary NGAL excretion to creatinine excretion. The NGAL/Cr ratio was significantly higher in diabetic patients than in healthy controls, but no statistically significant difference was found between the diabetic patients with and without albuminuria. Conclusions: Urinary NGAL excretion in type 1 diabetic patients is found to be increased over a wide range, but it does not correlate with urinary albumin excretion. In this regard, urinary NGAL excretion should not be used as an alternative to microalbuminuria in detecting diabetic nephropathy. The greater amount of NGAL excretion among diabetic patients may be due to diabetic nephropathy with possible tubulointerstitial damage pathologies.

العلاقة: Makale - Uluslararası Hakemli Dergi; Clinical Laboratory; Sanayi; Şişman, P. vd. (2020). "Urinary neutrophil gelatinase-associated lipocalin (NGAL) as a marker of diabetic nephropathy in type 1 diabetic patients". Clinical Laboratory, 66(1,2), 9-16.; https://doi.org/10.7754/Clin.Lab.2019.190326Test; https://www.clin-lab-publications.com/article/3270Test; http://hdl.handle.net/11452/34388Test; 000545455000002; 2-s2.0-85078933657; 16; 66; 1-2

الإتاحة: https://doi.org/10.7754/Clin.Lab.2019.190326Test
http://hdl.handle.net/11452/34388Test
https://www.clin-lab-publications.com/article/3270Test

المساهمون: Bursa Uludağ Üniversitesi/Mühendislik Fakültesi/Makine Mühendisliği., Demirkaya, Metin, GAF-3538-2022, 24331130000

مصطلحات موضوعية: Hodgkin lymphoma, Resistant, Relapsed disease, Programmed death 1 (PD-1) blocker, Nivolumab, Brentuximab vedotin, Phase-II, Cell transplantation, Response criteria, Pembrolizumab, Multicohort, Efficacy, Blockade, Failure, ABVD, Hematology, Adult, Allografts, Disease-free survival, Female, Follow-up Studies, Hodgkin disease, Humans, Male, Middle aged, Retrospective studies, Stem cell transplantation, Survival rate, Hodgkin's Disease, Refractory Materials

الوصف: Çalışmada 21 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır. ; Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in approximately one-third of the responding patients, the disease relapses following completion of therapy. One of the drugs that have been approved for the treatment of relapsed/refractory cHL is nivolumab, an immune check point inhibitor that shows its effects by blocking the programmed death 1 (PD-1) receptor. In this study, we present a retrospective “real-life” analysis of the usage of nivolumab in patients with relapsed/refractory cHL that have joined the named patient program (NPP) for nivolumab, reflecting 4 years of experience in the treatment of relapsed/refractory cHL. We present a retrospective analysis of 87 patients (median age, 30) that participated in the NPP in 24 different centers, who had relapsed/refractory cHL and were consequently treated with nivolumab. The median follow-up was 29 months, and the median number of previous treatments was 5 (2–11). In this study, the best overall response rate was 70% (CR, 36%; PR, 34%). Twenty-eight of the responding patients underwent subsequent stem cell transplantation (SCT). Among 15 patients receiving allogeneic stem cell transplantation, 9 patients underwent transplantation with objective response, of which 8 of them are currently alive with ongoing response. At the time of analysis, 23 patients remained on nivolumab treatment and the rest discontinued therapy. The main reason for discontinuing nivolumab was disease progression (n = 23). The safety profile was acceptable, with only nine patients requiring cessation of nivolumab due to serious adverse events. The 24-month progression-free and overall survival rates were 58.5% (95% CI, 0.47–0.68) and 78.7% (95% CI, 0.68–0.86), respectively. Eighteen patients died during the follow-up and only one of these was regarded to be treatment-related. With its efficacy and its safety profile, PD-1 blockers became an ...

العلاقة: Makale - Uluslararası Hakemli Dergi; Annals of Hematology; Yurt içi; Sanayi; Beköz, S. vd. (2020). "Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience". Annals of Hematology, 99(11), 2565-2576.; https://link.springer.com/article/10.1007/s00277-020-04077-4Test; https://hdl.handle.net/11452/39491Test; 000538693900001; 2-s2.0-85086129098; 2565; 2576; 99; 11; https://doi.org/10.1007/s00277-020-04077-4Test

الإتاحة: https://doi.org/10.1007/s00277-020-04077-4Test
https://hdl.handle.net/11452/39491Test

المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/Fizik Tedavi ve Rehabilitasyon Anabilim Dalı., Alp, Alev, ABG-2019-2020, 56256023200

مصطلحات موضوعية: Rehabilitation, Aerobic exercise, Bone-spesific alkaline phosphatase, Cross linked c telopeptide of type 1 collagen, Postmenopausal women, Perimenopausal women, Biochemical markers, Physical-activity, Mineral density, Mass, Osteoporosis, Metaanalysis, Weight, Health, Bone Health, Bone Density, Photon Absorptiometry, Alkaline phosphatase, Carboxy terminal telopeptide, Adult, Article, Blood pressure, Bone turnover, Chemical analysis, Controlled study, Cooling, Female, Human, Middle aged, Osteolysis

الوصف: Objective: This study aimed to investigate the effects of moderate-intensity aerobic exercise on bone turnover by urinary cross-linked C-telopeptide of type I collagen (CTX) and serum bone-spesific alkaline phosphatase (BAP) in comparison with a control group. Materials and Methods: 100 premenopausal volunteers from our outpatient unit were randomized into 2 equal groups. The exercise group (n=50) performed the exercise sessions supervised by a physiotherapist for 40 min a day, 5 times a week for a duration of 2 months. The control group (n=50) maintained their sedentary lifestyle for the duration. Urinary CTX and BAP levels in the subjects were measured before and at the end of the intervention. Results: The changes in CTX and BAP from baseline were statistically significant in the exercise group for but not in the control group. When the groups were compared with each other, the exercise group was found to be superior to the control group for the change in CTX. Conclusion: Two months of regular submaximal aerobic exercise decreased bone resorption rate in premenopausal sedentary women

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi-Turkish Journal of Physical Medicine and Rehabilitation; Alp, A. (2013). “Effects of aerobic exercise on bone-specific alkaline phosphatase and urinary CTX levels in premenopausal women”. Türkiye Fiziksel Tip ve Rehabilitasyon Dergisi-Turkish Journal of Physical Medicine and Rehabilitation, 59(4), 310-313.; https://www.ftrdergisi.com/uploads/sayilar/196/buyuk/310-3131.pdfTest; https://hdl.handle.net/11452/40916Test; 000340589000008; 2-s2.0-84891652464; 310; 313; 59; https://doi.org/10.4274/tftr.93546Test

الإتاحة: https://doi.org/10.4274/tftr.93546Test
https://hdl.handle.net/11452/40916Test
https://www.ftrdergisi.com/uploads/sayilar/196/buyuk/310-3131.pdfTest